Rice University bioengineers create insulin-producing medical device

health tech

Rice University bioengineers are designing a vascularized, insulin-producing implant for Type 1 diabetes. Photo by Jeff Fitlow courtesy of Rice University

A team of bioengineers at Houston's own Rice University have created an implant that can produce insulin for Type 1 diabetics. The device is being created by using 3D printing and smart biomaterials.

Omid Veiseh, an assistant professor of bioengineering, and Jordan Miller, associate professor of bioengineering, have been working on the project for three years and have received support from JDRF by way of a grant. Veiseh has a decade of experience developing biomaterials that protect implanted cell therapies from the immune system an Miller has spent more than 15 years specializing in 3D print tissues with vasculature, or networks of blood vessels.

"If we really want to recapitulate what the pancreas normally does, we need vasculature," Veiseh says in a news release. "And that's the purpose of this grant with JDRF. The pancreas naturally has all these blood vessels, and cells are organized in particular ways in the pancreas. Jordan and I want to print in the same orientation that exists in nature."

The challenge with Type 1 diabetes is balancing insulin intake, and studies estimate that less than a third of Type 1 diabetics in the U.S. are able to achieve target blood glucose levels consistently. Veiseh and Miller are working toward demonstrating that their implants can properly regulate blood glucose levels of diabetic mice for at least six months. To do that, they'll need to give their engineered beta cells the ability to respond to rapid changes in blood sugar levels.

"We must get implanted cells in close proximity to the bloodstream so beta cells can sense and respond quickly to changes in blood glucose," Miller says, adding that the insulin-producing cells should be no more than 100 microns from a blood vessel. "We're using a combination of pre-vascularization through advanced 3D bioprinting and host-mediated vascular remodeling to give each implant several shots at host integration."

Another challenge these experts are facing is a potential delay that can happen if the implant is too slow to respond to high or low blood sugar levels.

"Addressing that delay is a huge problem in this field," Veiseh says. "When you give the mouse — and ultimately a human — a glucose challenge that mimics eating a meal, how long does it take that information to reach our cells, and how quickly does the insulin come out?"

By incorporating blood vessels in their implant, he and Miller hope to allow their beta-cell tissues to behave in a way that more closely mimics the natural behavior of the pancreas.

Last month was National Diabetes Awareness Month and Houston-based JDRF Southern
Texas Chapter has some examples of how technology is helping people with type 1 diabetes. Photo courtesy of JDRF

Houston expert: New technologies are improving lives of those living with type 1 diabetes

Guest column

Type 1 diabetes (T1D) is an autoimmune disease where insulin-producing beta cells in the pancreas are mistakenly destroyed by the body's immune system. Insulin is vital in controlling blood-sugar or glucose levels. Not only do you need proper blood-sugar levels for day-to-day energy, but when blood-sugar levels get too high (hyperglycemia) or too low (hypoglycemia), it can cause serious problems and even death. Because of this, those with T1D are dependent on injections or pumps to survive.

The causes of T1D are not fully known, and there is currently no cure; however, advancing technologies are making it easier to live with T1D.

Monitoring

Those who have had T1D for decades might recall having to pee into a vial and test reagent strips in order to check their blood-sugar levels. Thankfully, this evolved into glucometers, or glucose meters. With a glucometer, those with T1D prick their finger and place a drop on the edge of the test strip, which is connected to the monitor that displays their results. Nowadays, glucometers, much like most T1D tech, can be Bluetooth enabled and sync with a smartphone.

From there, scientists have developed the continuous glucose monitor (CGM) so that those with T1D can monitor their blood sugar 24/7. All you need to do is insert a small sensor under the skin. The sensor then measures glucose levels every few minutes, and that information can then be transmitted to smartphones, computers and even smart watches.

Monitoring blood-sugar levels is vital for those with T1D, particularly because it helps them stay more aware of their body, know what to do and even what to expect, but they also have to actively control those levels by injecting insulin. Think of a monitor as the "check engine" light. It can tell you that there may be a problem, but it won't fix it for you. To fix it, you would need an injection or a pump.

Pumps and artificial pancreas

The development of insulin pumps has made a huge impact on the lives of those with T1D and parents of children with T1D by making it easier to manage their blood-sugar levels. 50 years ago, the prototype of the insulin pump was so large, it had to be a backpack, but with today's technology, it is about the size of a smartphone. The pump is worn on the outside of the body, and it delivers insulin through a tube which is placed under the skin. Insulin pumps mimic the way a pancreas works by sending out small doses of insulin that are short acting. A pump can also be manipulated depending on each person's needs. For example, you can press a button to deliver a dose with meals and snacks, you can remove it or reduce it when active and it can be programmed to deliver more at certain times or suspend delivery if necessary.

One of the most recent and trending developments in T1D research is the artificial pancreas, or more formally referred to as the automated insulin delivery (AID) systems. Essentially, the artificial pancreas is an insulin pump that works with a CGM. The CGM notifies the insulin pump of your blood-sugar reading, which acts accordingly to restore your blood sugar to the target level. The artificial pancreas allows those with T1D to be even more hands off, as it does essentially everything: It continuously monitors blood-sugar levels, calculates how much insulin you would need, which can be done through smart devices, and automatically delivers insulin through the pump.

Living with T1D is a 24/7/365 battle; however, the advances in technology make it easier and safer to live with the disease. Organizations like JDRF play a huge role in investing in research, advocating for government support and more.

November was National Diabetes Awareness Month, and this year is particularly special for JDRF, as it is the 50th year of the organization. JDRF was founded in 1970 by two moms. The community grew to include scientists, lobbyists, celebrities and children—all determined to improve lives and find cures.

Bound by a will stronger than the disease, this year during National Diabetes Awareness Month (NDAM), JDRF celebrates "The Power of Us." We are reflecting on the power of our community and reminding ourselves and the public of how far we've come in the fight against T1D.


------

Rick Byrd is the executive director of the JDRF Southern Texas Chapter.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston's Ion District to expand with new research and tech space, The Arc

coming soon

Houston's Ion District is set to expand with the addition of a nearly 200,000-square-foot research and technology facility, The Arc at the Ion District.

Rice Real Estate Company and Lincoln Property Company are expected to break ground on the state-of-the-art facility in Q2 2026 with a completion target set for Q1 2028, according to a news release.

Rice University, the new facility's lead tenant, will occupy almost 30,000 square feet of office and lab space in The Arc, which will share a plaza with the Ion and is intended to "extend the district’s success as a hub for innovative ideas and collaboration." Rice research at The Arc will focus on energy, artificial intelligence, data science, robotics and computational engineering, according to the release.

“The Arc will offer Rice the opportunity to deepen its commitment to fostering world-changing innovation by bringing our leading minds and breakthrough discoveries into direct engagement with Houston’s thriving entrepreneurial ecosystem,” Rice President Reginald DesRoches said in the release. “Working side by side with industry experts and actual end users at the Ion District uniquely positions our faculty and students to form partnerships and collaborations that might not be possible elsewhere.”

Developers of the project are targeting LEED Gold certification by incorporating smart building automation and energy-saving features into The Arc's design. Tenants will have the opportunity to lease flexible floor plans ranging from 28,000 to 31,000 square feet with 15-foot-high ceilings. The property will also feature a gym, an amenity lounge, conference and meeting spaces, outdoor plazas, underground parking and on-site retail and dining.

Preleasing has begun for organizations interested in joining Rice in the building.

“The Arc at the Ion District will be more than a building—it will be a catalyst for the partnerships, innovations and discoveries that will define Houston’s future in science and technology,” Ken Jett, president of Rice Real Estate Company, added in the release. “By expanding our urban innovation ecosystem, The Arc will attract leading organizations and talent to Houston, further strengthening our city’s position as a hub for scientific and entrepreneurial progress.”

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

Houston team develops low-cost device to treat infants with life-threatening birth defect

infant innovation

A team of engineers and pediatric surgeons led by Rice University’s Rice360 Institute for Global Health Technologies has developed a cost-effective treatment for infants born with gastroschisis, a congenital condition in which intestines and other organs are developed outside of the body.

The condition can be life-threatening in economically disadvantaged regions without access to equipment.

The Rice-developed device, known as SimpleSilo, is “simple, low-cost and locally manufacturable,” according to the university. It consists of a saline bag, oxygen tubing and a commercially available heat sealer, while mimicking the function of commercial silo bags, which are used in high-income countries to protect exposed organs and gently return them into the abdominal cavity gradually.

Generally, a single-use bag can cost between $200 and $300. The alternatives that exist lack structure and require surgical sewing. This is where the SimpleSilo comes in.

“We focused on keeping the design as simple and functional as possible, while still being affordable,” Vanshika Jhonsa said in a news release. “Our hope is that health care providers around the world can adapt the SimpleSilo to their local supplies and specific needs.”

The study was published in the Journal of Pediatric Surgery, and Jhonsa, its first author, also won the 2023 American Pediatric Surgical Association Innovation Award for the project. She is a recent Rice alumna and is currently a medical student at UTHealth Houston.

Bindi Naik-Mathuria, a pediatric surgeon at UTMB Health, served as the corresponding author of the study. Rice undergraduates Shreya Jindal and Shriya Shah, along with Mary Seifu Tirfie, a current Rice360 Global Health Fellow, also worked on the project.

In laboratory tests, the device demonstrated a fluid leakage rate of just 0.02 milliliters per hour, which is comparable to commercial silo bags, and it withstood repeated disinfection while maintaining its structure. In a simulated in vitro test using cow intestines and a mock abdominal wall, SimpleSilo achieved a 50 percent reduction of the intestines into the simulated cavity over three days, also matching the performance of commercial silo bags. The team plans to conduct a formal clinical trial in East Africa.

“Gastroschisis has one of the biggest survival gaps from high-resource settings to low-resource settings, but it doesn’t have to be this way,” Meaghan Bond, lecturer and senior design engineer at Rice360, added in the news release. “We believe the SimpleSilo can help close the survival gap by making treatment accessible and affordable, even in resource-limited settings.”
View All Listings